Clinical Trial

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Study acronym: IL-2-AD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Study aims at evaluating the therapeutic efficacy and safety of low-dose IL-2 immunomodulatory treatment in patients with early AD, in a phase II, randomized, double blind, placebo-controlled phase II clinical trial. Patients with AD at early stage will be recruited and randomized (2:1) in each treatment group. The primary endpoint is the rate of decline assessed through CDR change at 18 months between the placebo group and the treated patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-07-18; most recent amendment 2026-07-20.
Status change: Recruiting → Active, Not Recruiting 2026-07-20
Status change: Not Yet Recruiting → Recruiting 2022-10-14
Trial Details
NCT Number NCT05468073
Lead Sponsor Centre Hospitalier St Anne
Collaborators: For Drug Consulting
Conditions Alzheimer Disease
Enrollment 40 participants
Start Date 2022-10-11
Primary Completion 2028-06-08 (estimated)
Study Completion 2028-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-22